Evidence map›Paper›PMID 25942561›Full record

ArticlePloS one2015

Apolipoprotein B48, the Structural Component of Chylomicrons, Is Sufficient to Antagonize Staphylococcus aureus Quorum-Sensing.

Bradley O Elmore, Kathleen D Triplett, Pamela R Hall

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Interaction BetweenCurrent pharmaceutical biotechnology · 2026
    Review
  2. Article
  3. Biofilm Formation ofMicroorganisms · 2023
    Review
  4. Chemical and biomolecular insights into theIsrael journal of chemistry · 2023
    Article
  5. Angewandte Chemie (International ed. in English) · 2022
    Article
  6. Review
  7. Article
  8. Article
  9. Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens.International journal of molecular sciences · 2019
    Review
  10. Regulation ofMicrobiology spectrum · 2019
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Bradley O ElmoreDepartment of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, United States of America.
Kathleen D TriplettDepartment of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, United States of America.
Pamela R HallDepartment of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, United States of America.
University of New Mexico · US

Funding

Apolipoprotein B and Control of S. aureus Quorum SensingR01AI091917 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI HALL, PAMELA RANEL · 2011 to 2015
$1.9M
NIAID NIH HHS AI091917NIAID NIH HHS R01 AI091917
6 · The paper itself

Abstract

Serum lipoproteins (LP) are increasingly being recognized as dual purpose molecules that contribute to both cholesterol homeostasis and host innate defense. In fact, very low LP levels are associated with increased risk of bacterial infection in critically ill patients. In this respect, we reported that apolipoprotein B100 (apoB100), the 4536 amino acid structural protein of very low density lipoprotein (VLDL) produced by the liver, limits Staphylococcus aureus pathogenesis. S. aureus uses quorum-sensing (QS) via the accessory gene regulator (agr) operon and an autoinducing peptide (AIP) to coordinate expression of over 200 virulence genes. ApoB100 prevents agr activation by binding and sequestering secreted AIP. Importantly, human serum LP are produced not only by the liver, but are also produced by enterocytes, in the form of chylomicrons, during uptake of dietary lipids. In contrast to apoB100 in VLDL, human enterocytes use apoB48, the N-terminal 2152 amino acids (48%) of apoB100, as the structural component of chylomicrons. Interestingly, enteral feeding of critically ill patients has been associated with decreased risk of infectious complications, suggesting chylomicrons could contribute to host innate defense in critically ill patients when serum LP production by the liver is limited during the acute phase response. Therefore, we hypothesized that apoB48 would be sufficient to antagonize S. aureus QS. As expected, isolated apoB48-LP bound immobilized AIP and antagonized agr-signaling. ApoB48- and apoB100-LP inhibited agr activation with IC50s of 3.5 and 2.3 nM, respectively, demonstrating a conserved AIP binding site. Importantly, apoB48-LP antagonized QS, limited morbidity and promoted bacterial clearance in a mouse model of S. aureus infection. This work demonstrates that both naturally occurring forms of apolipoprotein B can antagonize S. aureus QS, and may suggest a previously unrecognized role for chylomicrons and enterocytes in host innate defense against S. aureus QS-mediated pathogenesis.

Indexed as

Quorum SensingAnimalsApolipoprotein B-100Apolipoprotein B-48Bacterial ProteinsChylomicronsHumansMiceMice, KnockoutModels, BiologicalPeptides, CyclicPromoter Regions, GeneticProtein BindingSignal TransductionStaphylococcal InfectionsStaphylococcus aureusAgrD protein, StaphylococcusAgr protein, Staphylococcus aureusApolipoprotein B-100Apolipoprotein B-48Bacterial ProteinsChylomicronsPeptides, CyclicTrans-Activators

Identifiers

PMID25942561
PMCPMC4420250
OpenAlexW262808358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.